PSMD1 and COVID-19: Since the onset of COVID-19 [3,4,5], the vaccine strategies that have been introduced to protect patients against severe forms of COVID-19 include mRNA-based technology, recombinant DNA (full-length SARS-CoV-2 spike), viral vector (full-length S or S1 spike subunit inserted in modified adenovirus vector or vaccinia vector), viral subunits (full-length S, S1, S receptor binding domain known as RBD sequence and nucleocapsid), virus-like particles (S, S1, RBD, or co-expression of S1, M and E proteins produced in baculovirus) and protein or peptide vaccines [6,7].